Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL

Optimal management of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) is dictated by patient characteristics, prior therapy, and response to prior therapy. We report the final analysis of combined fludarabine, cyclophosphamide, and rituximab (FCR) for previously treated patients...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Badoux, Xavier C., Keating, Michael J., Wang, Xuemei, O'Brien, Susan M., Ferrajoli, Alessandra, Faderl, Stefan, Burger, Jan, Koller, Charles, Lerner, Susan, Kantarjian, Hagop, Wierda, William G.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2011
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4123386/
https://ncbi.nlm.nih.gov/pubmed/21245487
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-08-304683
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars